Navigation Links
XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
Date:8/6/2008

XTELL has launched a commercial biorepository service, bioVAULT, which stores, manages and processes large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development.

Athens, OH (PRWEB) August 5, 2008 -- XTELL announced today the launch of its commercialized, independent biorepository service stemming from its collaborations with The Ohio University Endocrine Diseases Biorepository. XTELL's "bioVAULT" service will provide storage of biological samples derived from human/animal serum and tissues with 100% guaranteed confidentiality. BioVAULT will allow clinicians and researchers alike to facilitate and link patient/family medical history.

XTELL is a biotechnology company founded in 2001, dedicated to both the development of biological specimen storage and electronic medical record software.

A large part of XTELL's success has been from a direct partnership with Ohio University's Diabetes Center in creating a biorepository designed specifically for fundamental and translational research. Samples include DNA, RNA, and protein extracted from blood serum in patients living in a region of the United States with a high prevalence of diabetes and endocrine-related disease. XTELL has developed one of the most advanced diabetes biorepositories of its kind, with a state-of-the-art collection and storage facility.

BioVAULT is now capable of storing, managing and processing large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development, as well as universities. "Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics, " said Anthony Schwartz, President of XTELL.


XTELL is privately held and located in Athens, Ohio and is seeking new investors for building up its infrastructure as well as to secure its long-term growth.

Additional information is available at: http://www.xtell.com

Contact:
XTELL
Anthony Schwartz
President
Telephone: 1.800.314.0735
E-mail: info @ xtellnetworks.com

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1174534.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
2. Ingenuity Systems Launches Analysis Services
3. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
4. iNutrition Launches New Fission Fruit Nutrition Bars
5. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
6. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
7. Ranbaxy Launches Omeprazole 40 mg Capsules
8. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
9. GeneNews launches worlds first blood test for colorectal cancer screening
10. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
11. Health Market Science Launches Clinical Investigators(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies 
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):